Is erenumab (CGRP monoclonal antibody) appropriate for treating vestibular migraine, and what is the recommended dosing and monitoring?

Erenumab for Vestibular Migraine

Erenumab (70-140 mg subcutaneously monthly) is appropriate and effective for vestibular migraine, particularly when first-line preventive treatments (beta-blockers, topiramate, candesartan) have failed or are contraindicated.

Evidence Basis and Treatment Positioning

While current migraine guidelines position CGRP monoclonal antibodies as third-line preventive therapy for traditional migraine 1, emerging research specifically for vestibular migraine shows remarkably strong efficacy that may justify earlier use in this population. The evidence demonstrates that 90% of vestibular migraine patients achieved ≥50% reduction in vertigo frequency, 86% had ≥50% reduction in headache frequency, and 80% showed ≥50% reduction in migraine-related disability 2. This represents substantially better response rates than typically seen with conventional preventive medications.

The key distinction here is that vestibular migraine represents a specific, often treatment-refractory phenotype where CGRP-targeting therapies appear particularly effective 2, 3, 4, 5, 6, 7.

Recommended Treatment Algorithm

First-Line Approach (Standard Migraine Preventives)

• Beta-blockers: Propranolol, metoprolol, atenolol, or bisoprolol 1, 7
• Topiramate 1, 7
• Candesartan 1

Trial each for 2-3 months at therapeutic doses before declaring failure 1.

Second-Line Options

• Flunarizine
• Amitriptyline
• Sodium valproate (contraindicated in women of childbearing potential) 1

Third-Line: CGRP Monoclonal Antibodies (Including Erenumab)

However, for vestibular migraine specifically, consider moving to erenumab earlier if:

• Patient has failed 1-2 conventional preventives
• Vestibular symptoms are severely disabling
• Patient has contraindications to multiple first-line agents
• Prior medication overuse headache complicates treatment 2, 3, 7

Dosing and Administration

Standard Dosing

• Starting dose: 70 mg subcutaneously once monthly 8
• Higher dose: 140 mg subcutaneously once monthly for patients requiring greater efficacy 8, 9

Dosing Considerations

The FDA label indicates 70 mg as the recommended dose, with guidance that some patients may benefit from 140 mg 8. Evidence suggests the 140 mg dose shows numerically better efficacy across migraine outcomes, particularly in difficult-to-treat patients with prior treatment failures 9. For vestibular migraine, given the severity of functional impairment, initiating at 140 mg may be reasonable in selected patients, especially those with chronic migraine or multiple prior preventive failures 9, 10.

However, one real-world study found that escalating from 70 mg to 140 mg in non-responders provided minimal additional benefit 11. This suggests that if a patient shows no response to 70 mg after 3-6 months, switching to a different CGRP antibody or alternative therapy may be more effective than dose escalation 11.

Pharmacokinetics

• Peak serum concentration: ~6 days after injection 8
• Steady state: ~3 months 8
• Effective half-life: 28 days 8
• Bioavailability: 82% 8

Monitoring and Response Assessment

Timeline for Efficacy Assessment

• CGRP monoclonal antibodies require 3-6 months to assess efficacy 1—this is longer than conventional oral preventives (2-3 months)
• Do not abandon treatment prematurely; counsel patients that improvement may be gradual 1

Outcome Measures to Track

1. Monthly days with vestibular symptoms/dizziness (expect reduction from ~10 days to <1 day) 2
2. Monthly migraine days 2, 3, 10
3. Dizziness Handicap Inventory (DHI) score 3, 4, 7
4. Monthly acute medication use days 10
5. Headache Impact Test (HIT-6) score 10
6. ≥50% responder rate (primary efficacy endpoint) 2, 10

Objective Monitoring

Consider videonystagmography before and after treatment, as studies show normalization of vestibular instrumental findings (particularly positional nystagmus) with anti-CGRP therapy 3.

Safety Profile and Adverse Effects

Erenumab demonstrates a favorable safety profile comparable to placebo, with constipation being the only statistically significant adverse effect 10. No serious adverse events have been reported in vestibular migraine studies 2, 3, 4, 5.

Key Safety Points

• Well-tolerated in patients aged 18-78 years 11
• No significant drug interactions with cytochrome P450 substrates, oral contraceptives, or triptans 8
• No dose adjustment needed for mild-to-moderate renal impairment 8
• Severe renal impairment (eGFR <30) has not been studied 8

Contraindications and Precautions

• Pregnancy/lactation: No human data available; use only if benefit outweighs risk 8
• Discuss reproductive risks with patients of childbearing potential 12
• Not studied in pediatric populations 8

Treatment Duration and Discontinuation

• Trial duration: Minimum 3-6 months before assessing response 1
• Successful treatment: Consider pausing after 6-12 months of sustained efficacy to determine if ongoing therapy is necessary 1
• Treatment failure: If no response after 6 months, switch to alternative CGRP antibody (fremanezumab, galcanezumab) or different drug class 1

Clinical Pearls and Pitfalls

Common Pitfalls to Avoid

1. Premature discontinuation: Patients and providers may abandon treatment before 3-6 months, missing delayed therapeutic benefit 1
2. Inadequate trial of first-line agents: Ensure therapeutic doses of beta-blockers or topiramate for adequate duration before escalating to CGRP antibodies 1
3. Medication overuse headache: Address concurrent acute medication overuse (≥10 days/month for triptans, ≥15 days/month for NSAIDs) as this can limit preventive efficacy 12
4. Dose escalation in non-responders: Escalating from 70 mg to 140 mg in complete non-responders rarely provides benefit; consider switching agents instead 11

Optimizing Treatment Success

• Initiate early in disease course for better symptom control and quality of life 2
• Combine with vestibular rehabilitation as adjunct therapy for functional improvement 1, 7
• Address comorbidities: Depression, anxiety, sleep disturbances, and obesity can impact treatment response 1
• Lifestyle modifications: Adequate hydration, regular meals, consistent sleep, aerobic exercise, stress management 12

When to Refer to Specialist

• Chronic migraine with medication overuse headache 1
• Failure of multiple preventive treatments
• Diagnostic uncertainty (vestibular migraine vs. other vestibular disorders)
• Need for onabotulinumtoxinA (requires specialist administration) 1

Evidence Quality and Gaps

The evidence for erenumab in vestibular migraine consists entirely of observational studies (cohort studies, case series) with no randomized controlled trials 4, 5, 6. While the direction of effect is consistently positive across all studies, the absence of placebo-controlled trials, small sample sizes, and heterogeneous outcome reporting limit definitive conclusions 4, 5. Despite these limitations, the magnitude of benefit (90% responder rate for vertigo) and consistency across studies supports clinical use, particularly in refractory cases 2, 3, 4, 5, 7.

Adequately powered, double-blind, placebo-controlled RCTs are urgently needed 4, 5, 6.